Top

European Journal of Pediatrics

Published in:

01-11-2006 | Review

Population clinical pharmacology of children: general principles

Authors: Brian J. Anderson, Karel Allegaert, Nicholas H. G. Holford

Published in: European Journal of Pediatrics | Issue 11/2006

Abstract

Introduction

Population modelling using mixed-effects models provides a means to study variability in drug responses among individuals representative of those for whom the drug will be used clinically.

Discussion

The advantages of these models in paediatric studies are that they can be used to analyse sparse data, sampling times are not crucial and can be fitted around clinical procedures and individuals with missing data may still be included in the analysis. The introduction of explanatory covariates explains the predictable part of the between-individual variability. Simulations using parameter estimates and their variability can be used to investigate large numbers of children – many more than is possible in studies dealing with real children – for a fraction of the cost, which is an advantage when developing clinical trials. Paediatric population modelling has expanded greatly in the past decade and is now a routine procedure during the development and investigation of drugs. Children have benefitted and will continue to benefit from this approach.

Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer JL, van Peer A, Experts CB (2001) Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci 13:115–122PubMedCrossRef

Allegaert K, Anderson BJ, Cossey V, Holford NH (2006) Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 61:39–48PubMedCrossRef

Anderson BJ, Hansen TG (2004) Getting the best from pediatric pharmacokinetic data. Paediatr Anaesth 14:713–715PubMedCrossRef

Anderson BJ, Holford NHG, Armishaw JC, Aicken R (1999) Predicting concentrations in children presenting with acetaminophen overdose. J Pediatr 135:290–295PubMedCrossRef

Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E (2005) Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth 15:282–292PubMedCrossRef

Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 96:1336–1345PubMedCrossRef

Anderson BJ, Woollard GA, Holford NH (2000) A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 50:125–134PubMedCrossRef

Berde C (1992) Convulsions associated with pediatric regional anesthesia. Anesth Analg 75:164–166PubMedCrossRef

Bonate PL (1999) The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 16:709–717PubMedCrossRef

10.

Bond GR, Krenzelok EP, Normann SA, Tendler JD, Morris Kukoski CL, McCoy DJ, Thompson MW, McCarthy T, Roblez J, Taylor C et al (1994) Acetaminophen ingestion in childhood-cost and relative risk of alternative referral strategies. J Toxicol Clin Toxicol 32:513–525PubMedCrossRef

11.

Borowitz DS, Grand RJ, Durie PR (1995) Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr 127:681–684PubMedCrossRef

12.

Burns LE, Hodgman JE (1959) Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med 261:1318PubMedCrossRef

13.

D’Argenio D, Schumitzky A (1997) ADAPT II user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles

14.

D’Argenio DZ (1990) Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math Biosci 99:105–118PubMedCrossRef

15.

Duffull S, Waterhouse T, Eccleston J (2005) Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 32:441–457PubMedCrossRef

16.

Duffull SB, Kirkpatrick CM, Green B, Holford NH (2005) Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat 15:53–73PubMedCrossRef

17.

Efron B, Tibshirani R (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:54–77CrossRef

18.

Gill D (2004) Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr 163:53–57PubMedCrossRef

19.

Grasela TH Jr, Donn SM (1985) Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther 8:374–383PubMed

20.

Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, Mullen PW, Wadsworth J, Richens A, Ishizaki T, Chiba K et al (1983) Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 8:355–364PubMedCrossRef

21.

Grimsley C, Thomson AH (1999) Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed 81:F221–F227PubMed

22.

Holford NHG (2003) Input-ouput models. In: Kimko HC, Duffull SB (eds) Simulation for designing clinical trials. A pharmacokinetic-pharmacodynamic modeling perspective. Marcel Dekker, New York, pp 17–30

23.

Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ (1996) Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol 42:589–597PubMedCrossRef

24.

Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, Mandema JW, Shafer SL (1994) The pharmacokinetics of propofol in children using three different data analysis approaches [see comments]. Anesthesiology 80:104–122PubMedCrossRef

25.

Kauffman RE (1991) Fentanyl, fads, and folly: who will adopt the therapeutic orphans? J Pediatr 119:588–589PubMedCrossRef

26.

Meibohm B, Derendorf H (1997) Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35:401–413PubMed

27.

Meibohm B, Laer S, Panetta JC, Barrett JS (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7:E475–E487PubMedCrossRef

28.

Muller C, Kremer W, Harlfinger S, Doroshyenko O, Jetter A, Hering F, Hunseler C, Roth B, Theisohn M (2006) Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units. Eur J Pediatr 165:229–239PubMedCrossRef

29.

Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298–305PubMedCrossRef

30.

Pariente-Khayat A, Rey E, Gendrel D, Vauzelle-Kervroedan F, Cremier O, d’Athis P, Badoual J, Olive G, Pons G (1997) Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther 62:377–383PubMedCrossRef

31.

Peck CC, Beal SL, Sheiner LB, Nichols AI (1984) Extended least squares nonlinear regression: a possible solution to the “choice of weights” problem in analysis of individual pharmacokinetic parameters. J Pharmacokinet Biopharm 12:545–557PubMedCrossRef

32.

Peck CC, Sheiner LB, Nichols AI (1984) The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev 15:133–148PubMedCrossRef

33.

Pillai GC, Mentre F, Steimer JL (2005) Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 32:161–183PubMedCrossRef

34.

Ramet J (2005) What the paediatricians need-the launch of paediatric research in Europe. Eur J Pediatr 164:263–265PubMedCrossRef

35.

Retout S, Mentre F (2003) Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn 30:417–443PubMedCrossRef

36.

Ribbing J, Jonsson EN (2004) Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn 31:109–134PubMedCrossRef

37.

Rombout F, Aarons L, Karlsson M, Man A, Mentre F, Nygren P, Racine A, Schaefer H, Steimer JL, Troconiz I, van Peer A (2004) Modelling and simulation in the development and use of anti-cancer agents: an underused tool? J Pharmacokinet Pharmacodyn 31:419–440PubMedCrossRef

38.

Saint-Raymond A, Seigneuret N (2005) Medicines for children: time for Europe to act. Paediatr Perinatal Drug Ther 6:142–146

39.

Sheiner LB, Beal SL (1980) Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8:553–571PubMedCrossRef

40.

Sheiner LB, Beal SL (1981) Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 9:635–651PubMedCrossRef

41.

Sheiner LB, Beal SL (1983) Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 11:303–319PubMedCrossRef

42.

Sheiner LB, Rosenburg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445–479PubMedCrossRef

43.

Taussig HB (1962) A study of the German outbreak of phocomelia: the thalidomide syndrome. JAMA 180:1106–1114PubMed

44.

Tett SE, NHG H, McLachlan AJ (1998) Population pharmacokinetics and pharmacodynamics: an underutilised resource. DIA Journal 32:693–710

45.

van der Marel CD, Anderson BJ, Pluim MA, de Jong TH, Gonzalez A, Tibboel D (2003) Acetaminophen in cerebrospinal fluid in children. Eur J Clin Pharmacol 59:297–302PubMedCrossRef

46.

Whiting B, Kelman AW, Grevel J (1986) Population pharmacokinetics. Theory and clinical application. [Review]. Clin Pharmacokinet 11:387–401PubMedCrossRef

47.

Wright PM (1998) Population based pharmacokinetic analysis: why do we need it; what is it; and what has it told us about anaesthetics? Br J Anaesth 80:488–501PubMed

48.

Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171–192PubMedCrossRef

Title: Population clinical pharmacology of children: general principles
Authors: Brian J. Anderson
Karel Allegaert
Nicholas H. G. Holford
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: European Journal of Pediatrics / Issue 11/2006
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-006-0188-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Population clinical pharmacology of children: general principles

Abstract

Introduction

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Discussion

Please log in to get access to this content

Other articles of this Issue 11/2006

Transumbilical embolization of hepatic arteriovenous malformation in a neonate with heart failure

Television watching at Greek paediatric hospitals

We will have to vaccinate healthy children against influenza when we know that it is helpful

Clinical findings and adverse outcome in neonates with symptomatic congenital cytomegalovirus (SCCMV) infection

Static and dynamic standing balance: test-retest reliability and reference values in 9 to 10 year old children

Seasonality in pediatric asthma admissions: the role of climate and environmental factors